Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We develop novel, targeted therapeutics for the treatment of cancer using our expertise in cancer biology, monoclonal antibodies, highly potent cytotoxic, or cell-killing, agents, and the design of linkers that enable these agents to be stably attached to the antibodies while in the blood stream and released in their fully active form after delivery to a cancer cell. An anticancer compound made using our Targeted Antibody Payload, or TAP, technology consists of a monoclonal antibody that binds specifically to an antigen target found on cancer cells with multiple copies of one of our proprietary cell-killing agents attached using one of our engineered linkers. Its antibody component enables a TAP compound to bind specifically to cancer cells that express a particular target antigen, the highly potent cytotoxic agent serves to kill the cancer cell, and the engineered linker controls the release and activation of the cytotoxic agent inside the cancer cell. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.95 |
| Quarterly EPS Est: | -0.3 |
| PEG Ratio: | -.02 |
|
Mean Recommendation: View Summary / View All |
2.42 |
Data is provided by Zacks Investment Research

